We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Ebolavirus' Soft Spot Uncovered

By Biotechdaily staff writers
Posted on 21 Jul 2008
The discovery of a lone protein that resides on the surface of the Ebolavirus could pave the way for new treatments that could render impotent a virus that, though rare, can kill up to 90% of the people it infects.

Researchers at the Scripps Research Institute (La Jolla, CA, USA) discovered that the so-called Ebolavirus glycoprotein (known as the ‘spike protein'), first discovered a decade ago, is wrapped in benign carbohydrates that mask the virus' deadliness, allowing it to elude immune system scouts. More...
The researchers made their discovery of the crystal structure of the glycoprotein by studying the bone marrow of a survivor of a 1995 Ebola outbreak in Kikwit (Democratic Republic of the Congo), and found that the trimeric Ebolavirus glycoprotein was bound to a neutralizing antibody. They then uncovered a putative receptor-binding site located deep in the chalice-shaped structure of Ebola's glycoprotein that latches onto the surface of host cells and thus gains entry into the cells. Access to the receptor site is restricted by a glycan cap and a protruding mucin-like domain. The discovery could pave the way for drugs designed to see through that protective coating and trigger the immune system to attack the virus before it can enter the cells. The study was published in the July 10, 2008, issue of Nature.

"It's the only thing that the virus puts on its surface that is absolutely critical for attaching to a host and driving into that host for infection,” said co-author Erica Ollmann Saphire, Ph.D., an assistant professor in the department of immunology. "The structure of the glycoprotein shows us the very few sites on its surface that are not cloaked by carbohydrate; these [sites] are the chink in the armor, or the Achilles' heel, that we can target antibodies against.”

Ebola is an incurable disease that was first discovered in 1976 in western Sudan and the eastern part of the Democratic Republic of the Congo (then known as Zaire). A person acquires the virus through contact with the bodily fluids of someone already infected. It can take from two days to three weeks for symptoms of Ebola to appear. The disease presents itself with a fever, muscle aches, and a cough before progressing to severe vomiting, diarrhea, and rashes, along with kidney and liver problems. Death generally occurs as the result of either one or a combination of dehydration, massive bleeding, and kidney and liver failure. The World Health Organization (WHO, Geneva, Switzerland) has so far documented 1,850 cases of Ebola, mostly in sub-Saharan Africa; only 600 (32%) of the victims survived. Since 1994, outbreaks of the virus have increased fourfold.


Related Links:
Scripps Research Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.